Design, synthesis and identification of novel colchicine-derived immunosuppressant

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4416-4420

  Chang, Dong Jo ^a   Yoon, Eun Young ^b   Lee, Geon Bong ^b   Kim, Soon Ok ^b   Kim, Wan Joo ^b   Kim, Young Myeong ^c   Jung, Jong Wha ^a   An, Hongchan ^a   Suh, Young Ger ^a  

^a Seoul National University   (South Korea)

^b Suwon University   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

Autoimmune disease; Colchicine; Cyclosporin A; Graft rejection; Immunosuppressant; Skin allograft; Transplantation

Indexed keywords

COLCHICINE; COLCHICINE DERIVATIVE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; RAT; SKIN ALLOGRAFT; STRUCTURE ACTIVITY RELATION;

ANIMALS; AUTOIMMUNE DISEASES; CHEMISTRY, PHARMACEUTICAL; COLCHICINE; CYCLOSPORINE; DRUG DESIGN; GOUT SUPPRESSANTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RATS; SKIN TRANSPLANTATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649922205     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.054     Document Type: Article

References (41)

1. Smith J.M., Nemeth T.L., and McDonald R.A. Prediatr. Clin. North. Am. 50 (2003) 1283
2. Calne R.Y., Rolles K., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., Craddock G.N., Aziz S., and Lewis P. Lancet 2 (1979) 1033
3. Borel, J. F. In Cyclosporin A; Borel, J. F., Eds.; Elsevier Biochemical Press: Amsterdam, 1982; pp 5-17.
4. Keown P.A. Drugs 40 (1990) 315
5. Handschumacher R.E., Harding M.W., Rice J., and Drugge R.J. Science 226 (1984) 544
6. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., and Schreiber S.L. Cell 66 (1991) 807
7. Wahrenberger A. Crit. Care. Nurs. Q 17 (1995) 27
8. Krulova M., Zajicova A., Fric J., and Holan V. Transpl. Int. 15 (2002) 108
9. Matsue H., Yang C., Matsue K., Edelbaum D., Mummert M., and Takashima A. J. Immunol. 169 (2002) 3555
10. Gummert J.F., Ikonen T., and Morris R.E. J. Am. Soc. Nephrol. 10 (1999) 1366
11. O'Shea J.J., Pesu M., Borie D.C., and Changelian P.S. Nat. Rev. Drug Disc. 3 (2004) 555
12. Hong J.C., and Kahan B.D. Semin. Nephrol. 20 (2000) 108
13. Chemnitius J. Prakt. Chem. 118 (1928) 29
14. Wilson L., and Meza I. J. Cell. Biol. 58 (1973) 709
15. Shelanski M.L., and Taylor E.W. J. Cell. Biol. 38 (1968) 304
16. Allen J.N., Herzyk D.J., and Wewers M.D. Am. J. Physiol. Lung Cell. Mol. Physiol. 261 (1991) 315
17. Stosic-Grujicic S., and Simic M.M. Cell. Immun. 69 (1982) 235
18. Freed B.M., Lempert N., and Lawrence D.A. Int. J. Immunopharmacol. 11 (1989) 459
19. Ding A.H., Porteu F., Sanchez E., and Nathan C.F. J. Exp. Med. 171 (1990) 715
20. Ostermann D., Perico N., Imberti O., Barbui C., Bontempelli M., and Remuzzi G. J. Am. Soc. Nephrol. 4 (1993) 1294
21. Bach F.H., Widmer M.B., Bach M.L., and Klein J. J. Exp. Med. 136 (1972) 1430
22. Kino T., Inamura F., Sakai K., Nakahara K., Goto T., and Okuhara M. Transplant. Proc. 19 (1987) 36
23. Lillehoj H.S. Infect. Immun. 55 (1987) 1616
24. Inamura N., Nakahara K., Kino T., Goto T., and Aoki H. Transplantation 45 (1988) 206
25. Lee S.J., Namkoong S., Ha K.S., Nam W.D., Kwon Y.G., Yoon E.Y., Chang D.J., Kim S.O., and Kim Y.M. Exp. Mol. Med. 39 (2007) 230
26. Wu C.J., Lovett M., Lee J.W., Moeller F., Kitamura M., Goralski T.J., Billingham M.E., Starnes V.A., and Clayberger C. Transplantation 54 (1992) 326
27. Strom T.B., Roy-Chaudhury P., Manfro R., Zheng X.X., Nickerson P.W., Wood K., and Bushell A. Curr. Opin. Immunol. 8 (1996) 688
28. Roozendaal R., Vellenga E., Postma D.S., De Monchy J.G.R., and Kauffman H.F. Immunology 98 (1999) 393
29. Eun J.S., Suh Y.H., Kim D.K., and Jeon H. Arch. Pharm. Res. 23 (2000) 531
30. Kwak H.J., Yang Y.S., Pae H.O., Kim Y.M., and Chung H.T. Mol. Cells 12 (2001) 178
31. Lebeau L., Ducray P., and Mioskowski C. Syn. Commun. 27 (1997) 293
32. Shi Q., Verdier-Pinard P., Brossi A., Hamel E., and Lee K.H. Bioorg. Med. Chem. 5 (1997) 2277
33. Dvorak Z., Ulrichova J., Pichard-Garcia L., Modriansky M., and Maurel P. Toxicol. In Vitro 16 (2002) 219
34. Worrall N.K., Lazenby W.D., Misko T.P., Lin T.S., Rodi C.P., Manning P.T., Tilton R.G., Williamson J.R., and Ferguson Jr. T.B. J. Exp. Med. 181 (1995) 63
35. Sandmeyer T. Ber. Dtsch. Chem. Ges. 17 (1884) 1633
36. Suzuki N., Azuma T., Kaneko Y., Izawa Y., Tomioka H., and Nomoto T. J. Chem. Soc., Perkin Trans. 1 (1987) 645
37. Because the parent compound (9b) of these analogues showed non-selective activity for B and T cells, we just performed lymphoproliferation assay on T-lymphocyte-activated cells as a general thing.
38. 50 value was expressed as greater than the highest exposure concentration. Each dose response curve is composed of a vehicle (DMSO) group and seven treatment groups spanning an exposure range of 0.1-300 μM. Each value in the curve represents the mean of 4-8 wells in a plate. The α-GST and MTT assays were run from one plate as were the GSH/8-isoprostane assays, while the cell proliferation and ATP assays were run from separate plates.
39. Vickers A.E.M. Cell. Biol. Toxicol. 10 (1994) 407
40. Redi H., Schlag G., and Paul E. Shock 3 (1995) 395
41. Huveneers-Oorsprong M.B.M., Hoogenbroom L.A.P., and Kuiper H.A. Toxicol. In Vitro 11 (1997) 385